Search results for " Vaccines"

showing 10 items of 472 documents

Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives

2022

La pandemia por COVID-19 ha supuesto un reto para los países y sus profesionales sanitarios. La entrada viral en el hospedador a través del receptor ACE-2 y una activación excesiva del sistema inmunológico son claves para comprender tanto la incidencia como la gravedad de la enfermedad. La enfermedad inflamatoria intestinal (EII) representa una condición especial asociada con una respuesta descontrolada del sistema inmunológico a agentes externos. Los tratamientos para la EII se han asociado con un mayor riesgo de infecciones bacterianas y virales. Esto ha planteado la cuestión de una posible mayor incidencia y gravedad de la infección por COVID-19 en pacientes con EII. A lo largo de este a…

medicine.medical_specialtyCOVID-19 VaccinesIBD-treatmentCOVID-19 VaccinePopulationDiseaseIncidencia por COVID-19COVID-19 graveInflammatory bowel diseaseSulfasalazineInternal medicinetratamiento de la EIIPandemicmedicineHumansEnfermedad Inflamatoria Intestina (EII)Inflammatory Bowel Disease (IBD)educationSevere COVID-19Pandemicseducation.field_of_studyTofacitinibHepatologybusiness.industryVacuna COVID-19Incidence (epidemiology)GastroenterologyRevisadoCOVID-19General Medicinemedicine.diseaseInflammatory Bowel DiseasesVaccinationCOVID-19 incidenceTumor Necrosis Factor Inhibitorsbusinessmedicine.drugGastroenterología y Hepatología (English Edition)
researchProduct

An Insight into the Role of Postmortem Immunohistochemistry in the Comprehension of the Inflammatory Pathophysiology of COVID-19 Disease and Vaccine-…

2021

On 11 March 2020, the World Health Organization (WHO) declared a pandemic due to the spread of COVID-19 from Wuhan, China, causing high mortality rates all over the world. The related disease, which mainly affects the lungs, is responsible for the onset of Diffuse Alveolar Damage (DAD) and a hypercoagulability state, frequently leading to Severe Acute Respiratory Syndrome (SARS) and multiorgan failure, particularly in old and severe-critically ill patients. In order to find effective therapeutic strategies, many efforts have been made aiming to shed light on the pathophysiology of COVID-19 disease. Moreover, following the late advent of vaccination campaigns, the need for the comprehension …

medicine.medical_specialtyCOVID-19 VaccinesQH301-705.5AutopsyReviewDiseaseCatalysisInorganic ChemistryvaccinePandemicHumansMedicineEndotheliumBiology (General)Physical and Theoretical ChemistryIntensive care medicineDiffuse alveolar damageAdverse effectQD1-999Molecular BiologypathophysiologySpectroscopypostmortemChAdOx1 nCov-19SARS-CoV-2business.industryMechanism (biology)Organic ChemistryCOVID-19ThrombosisGeneral MedicinePathophysiologyComputer Science ApplicationsVaccinationChemistryimmunohistochemistryCytokinesAutopsybusinessInternational Journal of Molecular Sciences
researchProduct

Italian association for the study of the liver position statement on SARS-CoV2 vaccination.

2021

The vaccination campaign against Sars-CoV-2 commenced in Italy at the end of December 2020. The first ones to receive the immunization against the virus were the health workers and the residents of nursing homes, following which the vaccine would be available for the entire population, beginning with the most vulnerable individuals. SARS-CoV2 vaccines have been demonstrated to be safe for the general population, although no data for patients with liver diseases or those having undergone liver transplantation are available so far. The present position statement AISF is an attempt to suggest, based on the published data on the impact of Sars-Cov-2 infection in patients with chronic liver dise…

medicine.medical_specialtyCOVID-19 VaccinesSars-CoV-2medicine.medical_treatmentPopulationLiver transplantationChronic liver diseaseRisk AssessmentPatient safetyEpidemiologyMedicineChronic liver disease Sars-CoV-2 Vaccination Humans Immunosuppressive Agents Italy Liver Transplantation Patient Safety Patient Selection Risk Adjustment Risk Assessment SARS-CoV-2 Transplant Recipients Treatment Outcome COVID-19 COVID-19 Vaccines Immunization Programs Liver DiseasesHumanseducationeducation.field_of_studyHepatologybusiness.industryImmunization ProgramsLiver DiseasesPatient SelectionChronic liver disease; Sars-CoV-2; VaccinationVaccinationChronic liver diseaseGastroenterologyCOVID-19medicine.diseaseTransplant RecipientsLiver TransplantationVaccinationTreatment OutcomeImmunizationItalyFamily medicineChronic liver disease; Sars-CoV-2; Vaccination; Humans; Immunosuppressive Agents; Italy; Liver Transplantation; Patient Safety; Patient Selection; Risk Adjustment; Risk Assessment; SARS-CoV-2; Transplant Recipients; Treatment Outcome; COVID-19; COVID-19 Vaccines; Immunization Programs; Liver DiseasesRisk AdjustmentPatient SafetyPosition PaperbusinessRisk assessmentImmunosuppressive AgentsDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

COVID-19 Vaccine: A Survey of Hesitancy in Patients with Celiac Disease

2021

(1) Background: COVID-19 vaccination campaigns offer the best hope of controlling the pandemic. However, the fast production of COVID-19 vaccines has caused concern among the general public regarding their safety and efficacy. In particular, patients with chronic illnesses, such as celiac disease (CD), may be more fearful. Information on vaccine hesitancy plays a pivotal role in the development of an efficient vaccination campaign. In our study, we aimed to evaluate COVID-19 vaccine hesitancy among Italian CD patients. (2) Methods: an anonymous questionnaire was sent to CD patients followed at our tertiary referral center for CD in Milan, Italy. Patients were defined as willing, hesitant an…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)ImmunologyCOVID-19 vaccinesDiseaseArticle03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoveryPandemicMedicinePharmacology (medical)Adverse effectPharmacologyResponse rate (survey)business.industryRCOVID-19Odds ratiovaccinesConfidence intervalVaccinationInfectious Diseases030220 oncology & carcinogenesisMedicinevaccine hesitancy030211 gastroenterology & hepatologybusinessCOVID-19 vaccineceliac diseaseVaccines
researchProduct

Epidemiological and virological studies into the poliomyelitis in Valencia (1959-1969)

2009

Studies into the polio virus began in Valencia in 1959 with the work undertaken by the microbiologist Vicente Sanchis-Bayarri Vaillant. After his education at the Rochester University and at the Pasteur Institute, Sanchis-Bayarri Vaillant established a laboratory of cell cultures at the Faculty of Medicine in Valencia, where he developed a new diagnostic technique for the poliomyelitis virus. In addition, epidemiological studies were carried out both prior to and post the 1963 vaccination campaign, which proved that Sabin’s oral vaccine was both effective and safe for use.

medicine.medical_specialtyEpidemiologyUNESCO::LINGÜÍSTICA::Lingüística aplicada::DocumentaciónPoliomielitisPoliomelitiscomplex mixtures:LINGÜÍSTICA::Lingüística aplicada::Documentación [UNESCO]History and Philosophy of ScienceCampañas de vacunaciónAZ20-999medicinePolio virusEpidemiologíaHistory of medicine. Medical expeditionsR131-687Poliomielitis; Poliovirus; Vacunas de la polio; Campañas de vacunación; Epidemiologíabusiness.industryPolio vaccinesPoliovirus Vaccinesmedicine.diseaseVaccination campaignsPoliomyelitisVaccinationPoliomyelitis virusPoliovirusVaccination CampaignsVacunas de la polioFamily medicinePolio virusHistory of scholarship and learning. The humanitiesbusinessPoliomyelitis
researchProduct

Knowledge about infection with human papillomavirus: a systematic review.

2007

Abstract Objective. Human papillomavirus (HPV) is a necessary cause of cervical cancer and genital warts. The aim of this systematic literature review was to provide an overview of knowledge about HPV infection among the public, students, patients and health professionals. Method. PubMed searches were performed and the results of studies were reported by age, gender, study population, country, recruitment score and year of study conduct. The recruitment score covered the mode of recruitment, study size and response rate. Results. We included 39 studies published between 1992 and 2006 covering a total of 19,986 participants. The proportion of participants who had heard of HPV varied from 13%…

medicine.medical_specialtyHealth Knowledge Attitudes PracticeEpidemiologyPopulationUterine Cervical NeoplasmsGenital wartsmedicineHumansPapillomavirus VaccinesRisk factoreducationPapillomaviridaeGynecologyCervical cancerResponse rate (survey)education.field_of_studybusiness.industryPapillomavirus InfectionsPublic Health Environmental and Occupational HealthHPV infectionvirus diseasesmedicine.diseaseSystematic reviewCondylomata AcuminataFamily medicinePopulation studyFemalebusinessPreventive medicine
researchProduct

HPV Vaccination: The Position Paper of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV)

2020

Human papillomavirus (HPV) related cervical cancer represents an issue of public health priority. The World Health Organization recommended the introduction of HPV vaccination in all national public programs. In Europe, vaccines against HPV have been available since 2006. In Italy, vaccination is recommended and has been freely offered to all young girls aged 11 years since 2008. Three prophylactic HPV vaccines are available against high- and low-risk genotypes. The quadrivalent vaccine contains protein antigens for HPV 6, 11, 16, and 18. The bivalent vaccine includes antigens for HPV 16 and 18. The nonavalent vaccine was introduced in 2014, and it targets HPV types 6, 11, 16, 18, 31, 33, 4…

medicine.medical_specialtyPathologycervical cancerprimary preventionImmunologylcsh:MedicineReviewHPV vaccinescervical intraepithelial neoplasiaCervical intraepithelial neoplasia03 medical and health sciences0302 clinical medicineDrug DiscoverymedicinePharmacology (medical)030212 general & internal medicineYoung adulthuman papillomavirusHPV vaccinePharmacologyColposcopyCervical cancermedicine.diagnostic_testbusiness.industryPublic healthlcsh:Rmedicine.diseaseVaccinationClinical trialSettore MED/40 - GINECOLOGIA E OSTETRICIAInfectious Diseases030220 oncology & carcinogenesisbusinessVaccines
researchProduct

Evaluation of varicella vaccine effectiveness as public health tool for increasing scientific evidence and improving vaccination programs

2020

Brazil; Chickenpox Vaccine; Humans; Immunization Programs; Public Health; Vaccination; Chickenpox; Viral Vaccines.

medicine.medical_specialtyVaricella vaccineMEDLINESettore MED/42 - Igiene Generale E ApplicataScientific evidenceChickenpox VaccineChickenpoxmedicineHumansChickenpox VaccineViral Vaccines.Immunization Programsbusiness.industryImmunization ProgramPublic healthViral VaccineVaccinationlcsh:RJ1-570Viral Vaccineslcsh:PediatricsVaccinationFamily medicinePediatrics Perinatology and Child HealthPublic HealthbusinessBrazilHumanJornal de Pediatria
researchProduct

The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes.

1998

The disappointing clinical results of cancer immunotherapy of the past few decades have not diminished the optimism about the potential of the new generation of immunotherapeutic strategies towards treatment of malignant disease. Tremendous progress has been made over recent years in unveiling the molecular basis of antigen presentation and recognition by cytotoxic T lymphocytes (CTL). The molecular concepts that have emerged from these studies have led to the design of novel anticancer vaccines and CTL-based immunotherapeutics. This review is to highlight the current molecular insights of antigen presentation and CTL recognition/activation, and their impact on the rational design of therap…

medicine.medical_treatmentAntigen presentationMolecular Sequence Datachemical and pharmacologic phenomenaCancer VaccinesImmune systemCancer immunotherapyNeoplasmsDrug DiscoverymedicineCytotoxic T cellAnimalsHumansAmino Acid SequenceGenetics (clinical)Antigen Presentationbusiness.industryImmunotherapyT lymphocyteMolecular medicineCTL*ImmunologyMolecular MedicineImmunotherapybusinessT-Lymphocytes CytotoxicJournal of molecular medicine (Berlin, Germany)
researchProduct

Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man.

2002

Mutations and aberrant expression of the p53 tumor suppressor protein are the most frequent molecular alterations in human malignancy. Peptides derived from the wild-type (wt) p53 protein and presented by major histocompatibility complex (MHC) molecules for T lymphocyte recognition are believed to serve as universal tumor-associated antigens for cancer immunotherapy. We studied the immunogeneicity of a recombinant replication-defective adenoviral vector encoding human full-length wt p53 (rAd/hup53) in human leukocyte antigen (HLA)-A2K(b)-transgenic (Tg) mice and man. The generation of p53 epitope-specific cytotoxic T lymphocytes (CTLs) in p53-proficient and p53-deficient A2K(b)-Tg mice was …

medicine.medical_treatmentGenetic VectorsEpitopes T-LymphocyteMice TransgenicPilot ProjectsHuman leukocyte antigenBiologyMajor histocompatibility complexCancer VaccinesEpitopeAdenoviridaeMiceImmune systemCancer immunotherapyAntigenSpecies SpecificityNeoplasmsHLA-A2 AntigenGeneticsmedicineCytotoxic T cellAnimalsHumansTreatment FailureMolecular BiologyT lymphocyteGenetic TherapyGenes p53Self ToleranceImmunologybiology.proteinMolecular MedicineTumor Suppressor Protein p53T-Lymphocytes CytotoxicGene therapy
researchProduct